Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 43.70 |
| Open | 43.90 |
| Bid | 43.85 x 1800 |
| Ask | 43.99 x 800 |
| Day's Range | 43.69 - 44.33 |
| 52 Week Range | 43.33 - 69.10 |
| Volume | |
| Avg. Volume | 15,909,956 |
| Market Cap | 89.172B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.10 |
| Earnings Date | Jul 26, 2024 |
| Forward Dividend & Yield | 2.40 (5.46%) |
| Ex-Dividend Date | Apr 04, 2024 |
| 1y Target Est | 49.03 |
ZacksThe Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
- Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GlobeNewswireEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
© 2024 Yahoo. All rights reserved.